Sacituzumab Tirumotecan With Pembrolizumab in Metastatic Non-small Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score ≥ 50%

Short Title: MK2870-007

Enrollment Status: Recruiting

NCT #: NCT06170788

Specialty Area: Oncology

Condition Studied: Metastatic Non-small Cell Lung Cancer (NSCLC) With PD-L1 TPS Greater Than or Equal to 50%

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To compare sacituzumab tirumotecan combined with pembrolizumab to pembrolizumab alone with respect to overall survival (OS).

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with advanced non-small cell lung cancer, squamous or nonsquamous
Confirmed PD-L1 expression in 50% or more of tumor cells
No indication for targeted therapy against epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or proto-oncogene tyrosine-protein kinase ROS1
No small cell lung cancer, moderate or severe nerve damage, severe eye conditions, inflammatory bowel disease, significant blood vessel disease of heart or brain, or organ or tissue transplant

What's Involved

Participation in the study will include:

Intravenous (IV) infusion of Pembrolizumab with or without the study medication

Principal Investigator

Katharine Thomas, MD

Oncology

A Member of

(775) 982–2820

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06170788

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews